UNIPHAR PLC EO -,08

Uniphar reports adjusted EPS of EUR 0.109 in H1 2026 (+11.2%), gross profit of EUR 236.5m (+7.7%) and EBITDA of EUR 61.1m (+6.2%). Return on capital employed (ROCE) was 14.7%, and free cash flow was negative at EUR -47m, which is attributed to timing effects in working capital. Management reaffirmed the mid‑term target of EUR 200m EBITDA by 2028 and expects double‑digit growth in Pharma and continued growth in Medtech; the commissioning of the new Greenogue 2 distribution centre has been delayed to February 2027. » Más en de.investing.com

Senior executives of Uniphar carried out share purchases and sales under the company’s share-based remuneration plan through the Uniphar plc Employee Benefit Trust. CEO Gerard Rabbette bought 111,088 ordinary shares and sold 233,068 ordinary shares; CFO Timothy Dolphin bought 74,059 and sold 155,378 ordinary shares — all transactions at €3.8629 per share. After the transactions Rabbette holds 7,334,772 and Dolphin holds 5,610,856 ordinary shares. The dealings were reported on Euronext Dublin via Intertrust Trustee (Ireland) Limited as trustee and are based on a disclosure under Article 19 of the Market Abuse Regulation. » Más en de.investing.com

Uniphar has scheduled its annual general meeting for 7 May 2026 at 11:00 in the premises of William Fry LLP in Dublin and has sent the annual report for the year ended 31 December 2025 to shareholders. Shareholders may attend in person, vote by proxy, or follow the meeting by telephone as listeners only; questions must be submitted in writing with the shareholder reference number by 5 May 2026 at 17:00. The notice, proxy form and annual report are available on the company website and for inspection at the registered office during normal business hours. » Más en de.investing.com